IMU

4.00%

4.8¢ imugene limited

Ann: Imugene onCARlytics Doses First Patient in IV Combination, page-204

First 204 Last

Share
Profile

Follow
Ragnarolf

165 Posts.

547

29/06/24

15:20

Post #: 74531838
Share

Originally posted by udaboy1: ↑

I agree. Weare going to know the results very quickly based on the mouse trials, I wouldsay from day 40. If they proceeds and recruit very quickly and move through the dose escalation cohorts and is announced publicly then Imugene will know they are onto something with OnCARlytics.
If you lookat the trial design published for the ASCO conference, the second part of the studyDose Escalation Combination Phase (which is where we are now),Blinatumomab is given to the patient on Day 2 continuously for 7 days, 1 weekoff for both CF33-CD19 and Blinatumomab, then repeat. 1 cycle for the combinationescalation is 28 days v the monotherapy escalation being 21 days for 1 cycle (2doses for CD-CD19). Note Blinatumomab is only given in 1 cycle for the OASIStrials (1^st dose 9micrograms and 2^nd dose 28micrograms). Hopefullythere’s enough payload in the missiles to do something to the solid tumors.Standard treatment for B cell (ALL) is up to 5 cycles. Patients who are incomplete remission after 2 cycles of induction treatment may receive up to 3additional cycles of consolidation treatment, based on an individualbenefit-risk assessment. Blinatumomab in NSW is so expensive @ AUD $77,360 per cycle.
https://www.eviq.org.au/haematology-and-bmt/leukaemias/acute-lymphoblastic-leukaemia/3404-acute-lymphoblastic-leukaemia-blinatumomab#:~:text=A%20single%20cycle%20of%20treatment,week)%20treatment%2Dfree%20interval.

We aregoing to know one way or the other whether if all the objectives of the trialsare met. Hoping for the best responses for the patients but if they don’t maybethe trials will find new therapeutics out of this OASIS trial.

OASIS Study Design from the ASCO Conference. You can find it on the Imugene website under Investors/Conference Presentation https://www.imugene.com/conference-presentations

Expand

Thanks mate, great info

IMU Price at posting: 5.7¢ Sentiment: None Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 8 more messages in this thread...

First 204 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.8¢		Change -0.002(4.00%)		Mkt cap ! $356.9M

Open	High	Low	Value	Volume
5.0¢	5.0¢	4.7¢	$2.298M	47.86M

Buyers (Bids)

No.	Vol.	Price($)
5	1925982	4.8¢

Sellers (Offers)

Price($)	Vol.	No.
4.9¢	3452098	12

View Market Depth

No.	Vol.	Price($)
5	1925982	0.048
44	6409183	0.047
52	5062868	0.046
58	6807888	0.045
13	2613180	0.044

Price($)	Vol.	No.
0.049	3452098	12
0.050	3513781	16
0.051	7159676	14
0.052	2071350	7
0.053	818882	6

Last trade - 16.10pm 27/09/2024 (20 minute delay)

IMU (ASX) Chart

Ann: Imugene onCARlytics Doses First Patient in IV Combination, page-204

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

ACCC seeks Olam divestments before it can buy Namoi Cotton

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Imugene onCARlytics Doses First Patient in IV Combination, page-204

Top Stories

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

ACCC seeks Olam divestments before it can buy Namoi Cotton

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News